Posts Tagged ‘For’

Acne Really Is A Nightmare For Some Teens

Posted by admin on Septiembre 17th, 2009 under dermatology
Tags: ,  •  No Comments

Zits, pimples, bumps and blemishes are a young persons worst nightmare. Collectively they are known as acne, a very common skin condition that affects millions of adolescents. Now a Norwegian study published in the open access journal BMC Public Health has investigated the links between acne, diet and mental health issues in both males and [...]

Risk For Weight Gain In Children May Be Increased By Certain Behavioral Traits And Feeding Practices

Posted by admin on Agosto 11th, 2009 under fitness obesity
Tags: , ,  •  No Comments

Many clinicians and public health officials view parental involvement as an essential part of solving the current childhood obesity epidemic. However, its important for parents to use the right approach when trying to combat childhood obesity. Restrictive feeding practices, or forbidding certain foods, may not always be the best solution. A childs inhibitory control, a [...]

FDA Approves Multaq(R) For Patients With Atrial Fibrillation Or Atrial Flutter

Posted by admin on Julio 3rd, 2009 under pharma industry
Tags: , ,  •  No Comments

Sanofiaventis (EURONEXT SAN and NYSE SNY) announced that the U.S. Food and Drug Administration (FDA) has approved Multaq(R) (dronedarone) 400 mg Tablets. Patients with atrial fibrillation (AF) or atrial flutter (AFL) soon will have a new treatment option to help improve current management of their disease. Multaq(R) is the first drug approved in the [...]

Takeda Receives FDA Complete Response Letter For Alogliptin, An Investigational Treatment For Type 2 Diabetes

Posted by admin on Junio 30th, 2009 under diabetes
Tags: ,  •  No Comments

Takeda Pharmaceutical Company Limited (”Takeda”) announced that Takeda Global Research & Development Center, Inc., a wholly owned United States (U.S.) subsidiary received on June 26 (U.S. time) a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the Companys New Drug Application (NDA) for alogliptin, a selective dipeptidyl peptidase IV (DPP4) inhibitor [...]

High-Intensity Focused Ultrasound For Localized Prostate Cancer: Initial Experience With A 2-Year Follow-Up

Posted by admin on Junio 7th, 2009 under prostate
Tags: , ,  •  No Comments

UroToday.com The diagnosis of localised prostate cancer is increasing due to increased awareness and increased testing. There are a number of treatment options available to many of these men, including surgery, radiotherapy, active surveillance and a range of new modalities including high intensity focused ultrasound (HIFU).Large numbers of men with localised disease are looking [...]

Patients In St. Jude Medical Deep Brain Stimulation For Depression Pilot Study Demonstrate Sustained Improvement In Depression Symptoms

Posted by admin on Mayo 22nd, 2009 under depression
Tags: ,  •  No Comments

According to the latest data in a clinical study supported by St. Jude Medical, Inc. (NYSESTJ), deep brain stimulation (DBS) therapy for depression may provide sustainable improvement in depression symptoms among patients with major depressive disorder. Study results will be presented at the American Psychiatric Association (APA) meeting in San Francisco.
This study profiles 21 [...]